New cancer drug shows promise in early trials for Tough-to-Treat tumors
NCT ID NCT07415863
Summary
This early-stage trial is testing a new drug called SYS6043 in people with advanced solid tumors that have spread or returned after standard treatments. Researchers will first determine safe dosage levels, then expand to study how the drug behaves in the body and whether it helps shrink tumors. The study involves 820 participants with various advanced cancers who have limited treatment options remaining.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.